Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use. ##STR00001##

The present invention discloses compounds that are useful in the treatment of respiratory diseases of animals, especially Bovine or Swine Respiratory disease (BRD and SRD).

The present invention discloses compounds that are useful in the treatment of respiratory diseases of animals, especially Bovine or Swine Respiratory disease (BRD and SRD).

The present invention provides intermediates useful for the synthesis of an aminopyrimidine derivative or pharmaceutically acceptable salt thereof having a selective inhibitory activity against protein kinases, especially against the protein kinases for mutant epidermal growth factor receptors; and processes for preparing the same. And also, the present invention provides novel intermediates useful for said process and processes for preparing the same.

Provided herein is the design and synthesis of novel molecular rotor fluorophores useful for detection of amyloid or amyloid like proteins. The fluorophores are designed to exhibit enhanced fluorescence emission upon associating with amyloid or amyloid like proteins as compared to unbound compound. Also disclosed herein are methods for treating diseases associated with amyloid or amyloid like proteins.

Provided herein is the design and synthesis of novel molecular rotor fluorophores useful for detection of amyloid or amyloid like proteins. The fluorophores are designed to exhibit enhanced fluorescence emission upon associating with amyloid or amyloid like proteins as compared to unbound compound. Also disclosed herein are methods for treating diseases associated with amyloid or amyloid like proteins.

The invention discloses a method for fluoroalkylation of enamines with a fluoro alkyl halide in the presence of a base.

The present invention relates to a compound of Formula la, lb and Ic, (Formula Ia) a pharmaceutical composition comprising the same and their use in the treatment or prevention of pathological conditions associated to depolarizing GABAergic transmission including, for example, Down syndrome and autism.

##STR00001##

The disclosure provides a naphthylurea compound having a formula I. R represents H, a C1-C5 straight-chain alkyl, a C1-C5 straight-chain alkyl with a halogen-substituted end or a 5-8-membered cycloalkyl; R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9 at each occurrence represent H, F, Cl, Br, —CN, —CH.sub.3, —CF.sub.3, —OCH.sub.3, or —OCF.sub.3; R.sub.5 optionally represents phenyl, and M is H or —CH.sub.3; m represents a number of CH.sub.2, and is 0 or 1; n represents a number of CH.sub.2, and is 1, 2, 3, or 4; and p represents a number of CH.sub.2, and is 2; and X is O or S.

The disclosure provides a naphthylurea compound having a formula I. R represents H, a C1-C5 straight-chain alkyl, a C1-C5 straight-chain alkyl with a halogen-substituted end or a 5-8-membered cycloalkyl; R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9 at each occurrence represent H, F, Cl, Br, —CN, —CH.sub.3, —CF.sub.3, —OCH.sub.3, or —OCF.sub.3; R.sub.5 optionally represents phenyl, and M is H or —CH.sub.3; m represents a number of CH.sub.2, and is 0 or 1; n represents a number of CH.sub.2, and is 1, 2, 3, or 4; and p represents a number of CH.sub.2, and is 2; and X is O or S.